Format

Send to

Choose Destination
See comment in PubMed Commons below
Osteoarthritis Cartilage. 2011 May;19(5):500-8. doi: 10.1016/j.joca.2010.10.031. Epub 2011 Mar 23.

Methodologic issues in clinical trials for prevention or risk reduction in osteoarthritis.

Author information

  • 1Thurston Arthritis Research Center, University of North Carolina, Chapel Hill, NC 27599-7280, USA. joanne_jordan@med.unc.edu

Abstract

The design and execution of prevention trials for OA have methodological issues that are distinct from trials designed to impact prevalent disease. Disease definitions and their precise and sensitive measurement, identification of high-risk populations, the nature of the intervention (pharmaceutical, nutraceutical, behavioral) and its potential pleiotropic impacts on other organ systems are critical to consider. Because prevention trials may be prolonged, close attention to concomitant life changes and co-morbidities, adherence and participant retention in the trial is of primary importance, as is recognition of the potential for "preventive misconception" and "behavioral disinhibition" to affect the ability of the trial to show an effect of the intervention under study. None of these potential pitfalls precludes a successful and scientifically rigorous process and outcome. As technology improves the means to measure and predict the OA process and its clinical consequences, it will be increasingly possible to screen individuals for high-risk phenotypes, combining clinical factors with information from imaging, genetic, metabolic and other biomarkers and to impact this high-risk condition to avoid or delay OA both structurally and symptomatically.

PMID:
21396470
PMCID:
PMC3260468
DOI:
10.1016/j.joca.2010.10.031
[PubMed - indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Support Center